Benign Prostatic Hyperplasia Therapeutics Market: Regional Study by Growth Rate, Driving Force, Sales, Revenue, Key Players, Forecast, 2018-2025

The growth of the global benign prostatic hyperplasia therapeutics market is majorly driven by the increase in male geriatric population. Other factors boosting the market growth include rise in awareness about prostate cancer and other urological disorders and increase in occurrence of benign prostatic hyperplasia patients across the world. However, inclination of patients toward minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hampers the market growth. Conversely, presence of strong pipeline products and high potential in untapped markets of the emerging economies are expected to provide lucrative growth opportunities for the global benign prostatic hyperplasia therapeutics market.

The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4708?utm_source=OPR

Benign prostatic hyperplasia (BPH) is a medical condition in which a males prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.

Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.

The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.

The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/4708?utm_source=OPR

North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017, and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.

The key players of the global benign prostatic hyperplasia therapeutics market include

• Abbott Laboratories,
• Allergan plc,
• Astellas Pharma, Inc.,
• Boehringer Ingelheim Pharma GmbH & Co. KG,
• Eli Lilly and Company,
• GlaxoSmithKline plc,
• Merck & Co., Inc.,
• Pfizer, Inc.,
• Sanofi, and
• Teva Pharmaceutical Industries Limited.

Table Of Content

Chapter: 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porter’s Five Forces analysis
3.4.1. Bargaining power of buyers
3.4.2. Bargaining power of suppliers
3.4.3. Threat of substitution
3.4.4. Threat of new entrant
3.4.5. Competitive rivalry
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in in geriatric population
3.5.1.2. Rise in prevalence of benign prostatic hyperplasia
3.5.1.3. Growth in the awareness related to urological disorders and prostate cancer
3.5.2. Restraints
3.5.2.1. High preferences for minimally invasive surgical therapies
3.5.3. Opportunities
3.5.3.1. Large number of products in pipeline
3.5.3.2. Opportunities in emerging economies
3.5.4. Impact analyses
3.6. Clinical trials

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/benign-prostatic-hyperplasia-therapeutics-market.html?utm_source=OPR

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.